Literature DB >> 8402644

p53 mutations and histological type of invasive breast carcinoma.

A Marchetti1, F Buttitta, S Pellegrini, D Campani, F Diella, D Cecchetti, R Callahan, M Bistocchi.   

Abstract

A polymerase chain reaction-single strand conformation polymorphism assay was used to assess p53 mutations in 148 invasive breast carcinomas, selected on the basis of their histotype. They comprised 56 lobular, 47 ductal, 19 mucinous, 18 medullary, and 8 papillary carcinomas. The distribution of p53 mutations was significantly different (P = 0.006) in the histotypes examined: mutations were frequent in medullary (39%) and ductal (26%), less common in lobular (12%), and absent in mucinous and papillary carcinomas. The frequency of mutations in the exon 5 of the p53 gene was significantly higher in medullary carcinomas than in the other histotypes: 5 (63%) of the mutations found in exon 5 were observed in medullary carcinomas (P = 0.012). One hundred twenty-two tumors from the total were also examined by immunohistochemistry for p53 overexpression using antibody PAb 1801. A specific immunostaining in neoplastic cells was present in 12 tumors. A strong correlation (P < 0.001) was observed between p53 mutations and nuclear accumulation of the p53 protein: 10 tumors were scored positive for both p53 mutation and overexpression. However, in 9 cases having a mutated p53 gene we failed to find a positive immunoreaction. A significant association (P = 0.01) was present between mutations in the p53 gene and high proliferative activity of the tumors determined by immunohistochemistry with monoclonal antibody Ki-67. Moreover, a significantly higher expression of the Ki-67 antigen was found in medullary carcinomas compared to the other histotypes. Our findings indicate that in invasive breast carcinomas structural abnormalities of the p53 gene are mainly seen in medullary and ductal tumors and that the other histological types, especially those associated with a high level of differentiation and favorable prognosis, show a very low incidence of p53 mutations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402644

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

Review 2.  The p53 tumor suppressor gene in breast cancer.

Authors:  R M Elledge; D C Allred
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  8p deletion is strongly linked to poor prognosis in breast cancer.

Authors:  P Lebok; A Mittenzwei; M Kluth; C Özden; B Taskin; K Hussein; K Möller; A Hartmann; A Lebeau; I Witzel; S Mahner; L Wölber; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; R Simon; G Sauter; L Terracciano; R Krech; A von der Assen; V Müller; E Burandt
Journal:  Cancer Biol Ther       Date:  2015-05-11       Impact factor: 4.742

4.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.

Authors:  M V González; M L Artímez; L Rodrigo; C López-Larrea; M J Menéndez; V Alvarez; R Pérez; M F Fresno; M J Pérez; A Sampedro; E Coto
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

5.  Microsatellite instability is uncommon in uterine serous carcinoma.

Authors:  H Tashiro; S F Lax; P B Gaudin; C Isacson; K R Cho; L Hedrick
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

6.  Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma.

Authors:  F Gonzalez-Palacios; M Sancho; J C Martinez; C Bellas
Journal:  Mol Pathol       Date:  1997-12

7.  Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

Authors:  J S Kovach; A Hartmann; H Blaszyk; J Cunningham; D Schaid; S S Sommer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

8.  Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Authors:  Patrick W B Derksen; Tanya M Braumuller; Eline van der Burg; Marten Hornsveld; Elly Mesman; Jelle Wesseling; Paul Krimpenfort; Jos Jonkers
Journal:  Dis Model Mech       Date:  2011-01-31       Impact factor: 5.758

9.  p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.

Authors:  M Barbareschi; O Caffo; C Doglioni; P Fina; A Marchetti; F Buttitta; R Leek; L Morelli; E Leonardi; G Bevilacqua; P Dalla Palma; A L Harris
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

10.  Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.

Authors:  M A Levesque; G M Clark; H Yu; E P Diamandis
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.